



**Amendments to the Claims**

1. (Currently Amended) A compound ~~prodrug of a hydroxamic acid derivative histone deacetylase (HDAC) inhibitor~~, represented by the structure of formula 1:




wherein R is a residue of a hydroxamic acid derivative histone deacetylase inhibitor; and  
 Ra is represented by the structure:



wherein R<sub>b</sub> and R<sub>c</sub> are independently of each other a hydrogen or an unsubstituted or substituted alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocyclyl, heteroaryl, alkylaryl, alkylcycloalkyl, alkylheterocyclyl, alkylheteroaryl or an amino acid residue; and  
 R<sub>d</sub> is hydrogen or an amino protecting group;


or a pharmaceutically acceptable salt, hydrate, solvate, polymorph or any combination thereof.

2. (Currently Amended) The compound ~~prodrug~~ according to claim 1, wherein R<sub>b</sub> and R<sub>c</sub> are independently of each other a hydrogen, methyl, ethyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, phenyl, benzyl, alkylphenyl, naphthyl or pyridyl.
3. (Currently Amended) The compound ~~prodrug~~ according to claim 1, wherein R<sub>a</sub> is selected from the group consisting of:



and wherein m is an integer of 1 to 10.


4. (Currently Amended) The compound ~~prodrug~~ according to claim 1, represented by the structure:



(2)

wherein each of R<sub>1</sub> and R<sub>2</sub> are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted, branched or unbranched alkyl, alkenyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, alkylcycloalkyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyloxy, aryloxy, or pyridine group, or R<sub>1</sub> and R<sub>2</sub> are bonded together to form a nitrogen containing heterocyclic ring optionally containing one or more additional heteroatoms, and n is an integer of 4 to 8.


5. (Currently Amended) The compound ~~prodrug~~ according to claim 1, represented by the structure:



(3)

wherein n is an integer of 4 to 8.

6. (Currently Amended) The compound ~~prodrug~~ according to claim 1, represented by the structure:




(4)

7. Cancelled.


(5)

8. Cancelled.

9. (Currently Amended) The compound prodrug according to claim 1, represented by the structure:




10. (Currently Amended) The compound prodrug according to claim 1, represented by the structure:




wherein  $\text{R}_1$  is a substituted or unsubstituted phenyl, piperidino, thiazolyl, 2-pyridinyl, 3-pyridinyl or 4-pyridinyl and  $n$  is an integer of 4 to 8.

11. (Currently Amended) The compound prodrug according to claim 1, represented by the structure:



wherein  $\text{R}_1$  is a substituted or unsubstituted phenyl, piperidino, thiazolyl, 2-pyridinyl, 3-pyridinyl or 4-pyridinyl and  $n$  is an integer of 4 to 8.


12. (Currently Amended) The compound prodrug according to claim 1, represented by the structure:



wherein A is an amide moiety,  $\text{R}_1$  and  $\text{R}_2$  are each selected from substituted or unsubstituted aryl, arylalkyl, naphthyl, cycloalkyl, cycloalkylamino, pyridineamino, piperidino, 9-purine-6-amino, thiazoleamino, hydroxyl, branched or unbranched alkyl, alkenyl, alkyloxy, aryloxy, arylalkyloxy, pyridyl, quinolinyl or isoquinolinyl; and  $n$  is an


integer of 3 to 10.

13. (Currently Amended) The compound prodrug according to claim 12, represented by the structure:




(13a)

14. (Currently Amended) The compound prodrug according to claim 12, represented by the structure:



(13b)


15. (Currently Amended) The compound prodrug according to claim 1, represented by the structure:




(14)

wherein A is an amide moiety, R<sub>1</sub> and R<sub>2</sub> are each selected from substituted or unsubstituted aryl, arylalkyl, naphthyl, cycloalkyl, cycloalkylamino, pyridineamino, piperidino, 9-purine-6-amino, thiazoleamino, hydroxyl, branched or unbranched alkyl, alkenyl, alkyloxy, aryloxy, arylalkyloxy, pyridyl, quinolinyl or isoquinolinyl; R<sub>3</sub> is hydrogen, a halogen, a phenyl or a cycloalkyl moiety and n is an integer of 3 to 10.

16. (Currently Amended) The compound prodrug according to claim 15, represented by the structure:




17. (Currently Amended) The compound prodrug according to claim 15, represented by the structure:




wherein n is an integer from about 3 to 10.

18. (Currently Amended) The compound prodrug according to claim 1, represented by the structure:




-wherein L is a linker selected from the group consisting of an amide moiety, O-, -S-, -NH-, NR, -CH<sub>2</sub>-, -(CH<sub>2</sub>)<sub>p</sub>-, -(CH=CH)-, phenylene, cycloalkylene, or any combination thereof wherein R is a substituted or unsubstituted C<sub>1</sub>-C<sub>5</sub> alkyl; and wherein each of R<sub>1</sub> and R<sub>2</sub> are independently a substituted or unsubstituted aryl, arylalkyl, naphthyl, cycloalkyl, cycloalkylamino, pyridineamino, piperidino, 9-purine-6-amino, thiazoleamino, hydroxyl, branched or unbranched alkyl, alkenyl, alkyloxy, aryloxy, arylalkyloxy, pyridyl, quinolinyl or isoquinolinyl; p is an integer of 0 to 10.


19. (Currently Amended) The compound prodrug according to claim 18, represented by the structure:



20. (Currently Amended) The compound prodrug according to claim 18, represented by the structure:



21. (Currently Amended) The compound prodrug according to claim 1, represented by the structure:



wherein


n is 2, 3, 4, 5, 6, 7 or 8;

q is 0 or 1;

p<sub>1</sub> and p<sub>2</sub> are independently of each other 0 or 1;

R<sub>1</sub> and R<sub>2</sub> are independently of each other an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, heterocyclyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl or alkylheterocyclyl; or when p<sub>1</sub> and p<sub>2</sub> are both 0, R<sub>1</sub> and R<sub>2</sub> together with the -CH<sub>2</sub>-N-CH<sub>2</sub>- group to which they are attached can also represent a nitrogen-containing heterocyclic ring; or when at least one of p<sub>1</sub> or p<sub>2</sub> is not 0, R<sub>1</sub> or R<sub>2</sub> or both can also represent hydrogen or alkyl.

22. (Currently Amended) The compound prodrug according to claim 1, represented by the structure:




(30)

wherein

n is 2, 3, 4, 5, 6, 7 or 8;

R<sub>1</sub> and R<sub>2</sub> are independently of each other a hydrogen or an unsubstituted or substituted alkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl or alkylheterocyclyl.

23. (Currently Amended) The compound prodrug according to claim 1, represented by the structure:




(31)

wherein

n is 2, 3, 4, 5, 6, 7 or 8;

R<sub>1</sub> and R<sub>2</sub> are independently of each other a hydrogen or an unsubstituted or substituted alkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl or alkylheterocyclyl.

24. (Currently Amended) The compound prodrug according to claim 1, represented by the structure:




(32)

wherein

n is 2, 3, 4, 5, 6, 7 or 8;

R<sub>1</sub> and R<sub>2</sub> are independently of each other an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, heterocyclyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl or alkylheterocyclyl; or R<sub>1</sub> and R<sub>2</sub> together with the -CH<sub>2</sub>-N-CH<sub>2</sub>- group to which they are attached can also represent a nitrogen-containing heterocyclic ring.

25. (Currently Amended) The compound prodrug according to claim 1, represented by the structure:




(33)

wherein

n is 2, 3, 4, 5, 6, 7 or 8;


R<sub>1</sub> and R<sub>2</sub> are independently of each other an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, heterocyclyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl or alkylheterocyclyl; or R<sub>1</sub> and R<sub>2</sub> together with the -CH<sub>2</sub>-N-CH<sub>2</sub>- group to which they are attached can also represent a nitrogen-containing heterocyclic ring.

26. (Currently Amended) The compound prodrug according to claim 1, represented by the structure:



(34)


wherein A is alkyl, aryl or a group selected from



wherein R<sub>1</sub>-R<sub>16</sub> are independently of each other a hydrogen or an unsubstituted or substituted alkyl, aryl, cycloalkyl, heterocyclyl, alkylaryl, alkylcycloalkyl or alkylheterocyclyl; or one or more of R<sub>1</sub> and R<sub>2</sub>, R<sub>6</sub> and R<sub>7</sub>, and R<sub>11</sub> and R<sub>12</sub>, together with the nitrogen atom to which they are attached, form a nitrogen-containing heterocyclic ring; and


l, p and q are independently of each other 0, 1 or 2.

27. (Currently Amended) The compound ~~prodrug~~ according to claim 1, represented by the structure:




wherein

A is alkyl, aryl or a group selected from:



wherein  $R_1$ - $R_{16}$  are independently of each other a hydrogen or an unsubstituted or substituted alkyl, aryl, cycloalkyl, heterocyclyl, alkylaryl, alkylcycloalkyl or alkylheterocyclyl; or one or more of  $R_1$  and  $R_2$ ,  $R_6$  and  $R_7$ , and  $R_{11}$  and  $R_{12}$ , together with the nitrogen atom to which they are attached, form a nitrogen-containing heterocyclic ring;

B is



$n$  is 0 or 1; and


$l$ ,  $p$  and  $q$  are independently of each other 0, 1 or 2.

28. (Currently Amended) A pharmaceutical composition comprising the compound prodrug of claim 1 or a pharmaceutically acceptable salt or hydrate thereof, and a pharmaceutically acceptable carrier.


29. ~~(Currently Amended) Use of the prodrug of claim 1 in the manufacture of a medicament~~ A method for the treatment of cancer comprising the step of administering to a mammal a therapeutically effective amount of the compound of claim 1.
30. Cancelled.
31. Cancelled.
32. Cancelled.
33. (New) The compound of claim 1 selected from the group consisting of:  
Octanedioic acid phenylamide (7-phenylcarbamoyl-heptanoyloxy)-amide;  
Octanedioic acid acetoxy-amide phenylamide;  
Octanedioic acid (biphenyl-4-carbonyloxy)-amide phenylamide;  
Octanedioic acid benzoyloxy-amide phenylamide;  
Octanedioic acid (naphthalene-2-carbonyloxy)-amide phenylamide;  
Octanedioic acid (naphthalene-1-carbonyloxy)-amide phenylamide;  
Octanedioic acid (3-methoxy-benzoyloxy)-amide phenylamide;  
Octanedioic acid (4-methoxy-benzoyloxy)-amide phenylamide;  
Octanedioic acid (2-methoxy-benzoyloxy)-amide phenylamide;  
Octanedioic acid (4-methyl-benzoyloxy)-amide phenylamide;  
Octanedioic acid (4-chloro-benzoyloxy)-amide phenylamide;  
Octanedioic acid (3-phenyl-acryloyloxy)-amide phenylamide;  
Octanedioic acid phenylamide (pyridine-3-carbonyloxy)-amide;  
Octanedioic acid (4-butyl-benzoyloxy)-amide phenylamide;  
Octanedioic acid phenylamide (3-phenyl-propionyloxy)-amide;  
Octanedioic acid phenylamide (4-phenyl-butyryloxy)-amide;  
[1-Benzyl-2-oxo-2-(7-phenylcarbamoyl-heptanoylaminoxy)-ethyl]-carbamic acid benzyl ester;  
and  
[1-Benzyl-2-oxo-2-(7-phenylcarbamoyl-heptanoylaminoxy)-ethyl]-carbamic acid tert-butyl ester;  
Or a stereoisomer thereof;  
Or a pharmaceutically acceptable salt thereof;

Or a pharmaceutically acceptable salt of the stereoisomer thereof.

34. (New) The compound of claim 1 that is



35. (New) The compound of claim 1 that is



36. (New) A pharmaceutical composition comprising the compound of claim 33 and a pharmaceutically acceptable carrier.
37. (New) A method for the treatment of cancer comprising the step of administering to a mammal a therapeutically effective amount of the compound of claim 33.